Max Healthcare Institute Limited has provided an update on petitions filed before the Hon’ble National Company Law Tribunal, Cuttack Bench. The petitions, involving BRS Capital Two Pte. Limited against Kalinga Hospital Ltd. (a subsidiary) and another shareholder, were heard on October 30, 2026. The NCLT has listed the matter for further consideration on December 14, 2026, and the company received a copy of the order passed today, November 3, 2026.
NCLT Proceedings Update
Max Healthcare Institute Limited has issued a disclosure regarding ongoing proceedings before the Hon’ble National Company Law Tribunal (NCLT), Cuttack Bench. This update follows a previous intimation dated October 29, 2026, concerning petitions, including interlocutory ones, filed by the legal representatives of BRS Capital Two Pte. Limited. These petitions are directed against Kalinga Hospital Ltd. (“KHL”), which is a subsidiary of Max Healthcare Institute Limited, as well as the other shareholder of KHL from whom the company acquired its majority equity stake.
Hearing and Order Status
The matter was listed for hearing on October 30, 2026, at 2:30 PM IST. The NCLT heard the case and, upon the request of all counsels, has scheduled further consideration for December 14, 2026. Additionally, Max Healthcare Institute Limited announced that it received a copy of the order passed by the Hon’ble NCLT today, November 3, 2026, at 2:13 PM IST.
Details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are enclosed as an annexure to this disclosure and will also be hosted on the company’s website, www.maxhealthcare.in.
Annexure Details
The annexure provides specific details concerning the proceedings. It confirms that the matter was heard by the NCLT on October 30, 2026, and subsequently listed for further consideration on December 14, 2026. The company also confirmed receiving the order copy on November 3, 2026. No litigation against key management personnel or promoters is involved, nor are there any settlement details to report at this stage.
Source: BSE
